News · Heart & Metabolic
Tirzepatide and semaglutide showed the same serious liver outcomes over about 17 months
Both drugs cut liver fat in trials, and patients often ask which is better for the liver. In health records of adults with obesity and diabetes, severe liver events were equally uncommon on each.
- An observational comparison of new users of tirzepatide and injectable semaglutide in global health records.
- All had overweight or obesity together with type 2 diabetes, a group at high risk of liver disease.
- Over about 17 months, serious liver events occurred in roughly 4 per 1,000 people a year on each drug.
- The result held in people with fatty liver disease and in an analysis limited to those still taking the drug.
- Tirzepatide produced slightly more weight loss, about 1.1 BMI points.
Fatty liver disease travels with obesity and type 2 diabetes, and it can end in cirrhosis. Both of the leading weight-loss injections cut liver fat in trials. So patients and doctors now ask a sharper question: does one of them hold off serious liver disease better than the other?
A study in the journal Obesity compared new users of tirzepatide and injectable semaglutide in a global network of health records. Over about 17 months, serious liver events were equally rare on both.
Why fatty liver matters in diabetes
MedlinePlus explains that steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver. Simple fatty liver, in which you have fat in your liver but little or no inflammation or liver damage, often stays harmless; the worse form brings inflammation and scarring that can end in cirrhosis.
That progression is what drug treatment aims to interrupt. The authors state the question directly: they set out to compare the effectiveness of tirzepatide versus injectable semaglutide in preventing major adverse liver outcomes (MALO) among adults with overweight or obesity and type 2 diabetes.
How tirzepatide and semaglutide were compared
This was a target trial emulation, which applies the rules of a hypothetical randomized trial to existing records. The researchers used the TriNetX global network to analyze new users of tirzepatide and semaglutide, then matched the two groups on their recorded characteristics.
The main measure was the time to a first serious liver event: cirrhosis, a decompensated complication or liver cancer. Median follow-up was about 17 months. The team also re-ran the comparison in different ways: among people who already had fatty liver disease, and counting only the time people were actually taking their drug.
What happened to liver outcomes
The two drugs landed in the same place. No significant difference in MALO risk was observed between tirzepatide and semaglutide initiators. Significant here means clearing a statistical threshold: the rates were 4.05 and 4.04 per 1,000 person-years, effectively identical.
The picture held up under pressure. Among people who already had fatty liver disease, rates were again almost identical, near 10 per 1,000 person-years in both groups, and the as-treated analysis agreed. The one clear difference was weight: tirzepatide achieved greater BMI reduction, by about 1.1 points.
Why a tie on liver outcomes is useful
Marketing and social media push the idea that one injection is simply better. For serious liver outcomes over this period, the data do not support a ranking, which simplifies the decision: choose on blood sugar, weight goals, side effects, heart and kidney needs, cost and supply.
The internal check is reassuring in a different way. Both drugs outperformed sitagliptin, an older diabetes tablet, in the researchers’ validation analysis, which suggests the comparison was capable of detecting a difference where one exists.
What a 17-month records comparison cannot show
Liver disease is slow. Cirrhosis and liver cancer typically take years to develop, and the number of events in 17 months is small, so a modest difference between the drugs could be invisible here.
Records-based comparisons carry the usual caveats. Prescribing is not random, matching balances only what is recorded, and doses, adherence and alcohol intake are poorly captured. Liver outcomes drawn from diagnostic codes can be incomplete. This also compares two active drugs, so it says nothing about either against no treatment.
What this changes for people on semaglutide or tirzepatide
If you have type 2 diabetes with overweight or obesity and worry about your liver, this study suggests the choice between these two injections is not a liver decision, at least in the short to medium term.
The measures that do protect the liver are the familiar ones: weight loss, blood sugar control, limiting alcohol, treating high blood pressure and cholesterol, and following up on abnormal liver tests. If fatty liver has been mentioned in your results, ask about a fibrosis assessment, which is what tells you whether scarring is present.
People also ask
What did the study find?
Over a median follow-up of about 17 months, rates of major adverse liver outcomes were 4.05 per 1,000 person-years with tirzepatide and 4.04 with semaglutide (hazard ratio 1.04, 95% CI 0.88 to 1.23). Results were similar in people with fatty liver disease and in an as-treated analysis. Tirzepatide achieved greater BMI reduction, a mean difference of about 1.1 kg/m2.
What counts as a major adverse liver outcome?
In this study, a combination of cirrhosis, decompensated liver disease, meaning complications such as fluid in the abdomen or bleeding veins, and liver cancer.
How do these drugs differ?
Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on GLP-1 and on a second gut hormone receptor, GIP, and tends to produce more weight loss.
Does this mean neither protects the liver?
No. The comparison was between the two drugs, not against no treatment. In an internal check, both outperformed an older diabetes drug, sitagliptin.
Is 17 months long enough?
Not for liver disease, which usually progresses over many years. Serious events were rare in this window, so a real difference could emerge later.
Should the liver decide which drug I take?
On this evidence, no. The choice usually rests on blood sugar and weight goals, side effects, heart and kidney considerations, cost and availability. This is general information rather than medical advice.